338 related articles for article (PubMed ID: 21779517)
1. p73 in Cancer.
Rufini A; Agostini M; Grespi F; Tomasini R; Sayan BS; Niklison-Chirou MV; Conforti F; Velletri T; Mastino A; Mak TW; Melino G; Knight RA
Genes Cancer; 2011 Apr; 2(4):491-502. PubMed ID: 21779517
[TBL] [Abstract][Full Text] [Related]
2. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression.
Saifudeen Z; Diavolitsis V; Stefkova J; Dipp S; Fan H; El-Dahr SS
J Biol Chem; 2005 Jun; 280(24):23094-102. PubMed ID: 15805112
[TBL] [Abstract][Full Text] [Related]
3. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2.
Sayan BS; Yang AL; Conforti F; Tucci P; Piro MC; Browne GJ; Agostini M; Bernardini S; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):12877-82. PubMed ID: 20615966
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma.
Lau LM; Wolter JK; Lau JT; Cheng LS; Smith KM; Hansford LM; Zhang L; Baruchel S; Robinson F; Irwin MS
Oncogene; 2009 May; 28(19):2024-33. PubMed ID: 19363520
[TBL] [Abstract][Full Text] [Related]
5. p73: From the p53 shadow to a major pharmacological target in anticancer therapy.
Ramos H; Raimundo L; Saraiva L
Pharmacol Res; 2020 Dec; 162():105245. PubMed ID: 33069756
[TBL] [Abstract][Full Text] [Related]
6. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
[TBL] [Abstract][Full Text] [Related]
7. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.
Nakagawa T; Takahashi M; Ozaki T; Watanabe K; Hayashi S; Hosoda M; Todo S; Nakagawara A
Cancer Lett; 2003 Jul; 197(1-2):105-9. PubMed ID: 12880968
[TBL] [Abstract][Full Text] [Related]
8. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
[TBL] [Abstract][Full Text] [Related]
9. Relative expression of TAp73 and ΔNp73 isoforms.
Conforti F; Yang AL; Agostini M; Rufini A; Tucci P; Nicklison-Chirou MV; Grespi F; Velletri T; Knight RA; Melino G; Sayan BS
Aging (Albany NY); 2012 Mar; 4(3):202-5. PubMed ID: 22388545
[TBL] [Abstract][Full Text] [Related]
10. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
11. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function.
Watson IR; Blanch A; Lin DC; Ohh M; Irwin MS
J Biol Chem; 2006 Nov; 281(45):34096-103. PubMed ID: 16980297
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
13. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
14. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific expression of p73 C-terminal isoforms in mice.
Grespi F; Amelio I; Tucci P; Annicchiarico-Petruzzelli M; Melino G
Cell Cycle; 2012 Dec; 11(23):4474-83. PubMed ID: 23159862
[TBL] [Abstract][Full Text] [Related]
16. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
Vayssade M; Haddada H; Faridoni-Laurens L; Tourpin S; Valent A; Bénard J; Ahomadegbe JC
Int J Cancer; 2005 Oct; 116(6):860-9. PubMed ID: 15849742
[TBL] [Abstract][Full Text] [Related]
17. DEC1 coordinates with HDAC8 to differentially regulate TAp73 and ΔNp73 expression.
Qian Y; Zhang J; Jung YS; Chen X
PLoS One; 2014; 9(1):e84015. PubMed ID: 24404147
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.
Hofstetter G; Berger A; Chamson M; Müller-Holzner E; Reimer D; Ulmer H; Uramoto H; Marth C; Zeimet AG; Zeillinger R; Concin N
Int J Gynecol Pathol; 2011 Nov; 30(6):527-31. PubMed ID: 21979586
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology.
Rossi M; Sayan AE; Terrinoni A; Melino G; Knight RA
Ann N Y Acad Sci; 2004 Dec; 1028():143-9. PubMed ID: 15650240
[TBL] [Abstract][Full Text] [Related]
20. The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas.
Domínguez G; Peña C; Silva J; García JM; García V; Rodríguez R; Cantos B; Citores MJ; España P; Bonilla F
J Pathol; 2006 Dec; 210(4):390-7. PubMed ID: 17029218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
